公开(公告)号：US20240122941A1

公开(公告)日：2024-04-18

申请号：US18258989

申请日：2021-12-24

申请人： NATIONAL CANCER CENTER ,  Sumitomo Pharma Co., Ltd.

发明人： Hideaki OGIWARA ,  Mariko SASAKI

IPC分类号： A61K31/553 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/431 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/675 ,  A61P35/00 ,  C12N9/10 ,  C12N9/99

CPC分类号： A61K31/553 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/431 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/675 ,  A61P35/00 ,  C12N9/1025 ,  C12N9/99

摘要： The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.